Literature DB >> 21767142

Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research.

Mariavittoria Dima1, Kelly A Miller, Valeria Gabriela Antico-Arciuch, Antonio Di Cristofano.   

Abstract

BACKGROUND: Poorly differentiated and anaplastic thyroid carcinomas have a rather poor prognosis. The development of relevant model systems to unravel in vitro and in vivo the molecular mechanisms governing the resistance of these tumors to therapy, as well as to test novel drug combinations, is a clear priority for thyroid-focused research.
METHODS: Several novel cell lines were established from tumors developed by mice engineered to simultaneously express a loss-of-function Pten allele and an oncogenic Kras allele.
RESULTS: Similar to most poorly differentiated thyroid tumors, these cell lines are characterized by simultaneous activation of the PI3K and MAPK pathways, by the presence of wild-type, functional p53, and by the severe downregulation of thyroid differentiation markers, including sodium-iodide symporter (NIS). Further, they display a highly glycolytic phenotype. They can be grafted to syngeneic, immunocompetent hosts, and easily metastasize to the lungs.
CONCLUSIONS: These mouse cell lines are a novel and invaluable tool that can be used to develop innovative therapeutic approaches to poorly differentiated carcinomas in a more physiological context than using xenografts of human cell lines in immunocompromised mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21767142      PMCID: PMC3162646          DOI: 10.1089/thy.2011.0030

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

Review 1.  Poorly differentiated and anaplastic thyroid cancer.

Authors:  Kepal N Patel; Ashok R Shaha
Journal:  Cancer Control       Date:  2006-04       Impact factor: 3.302

2.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

Review 3.  Oncogenic alterations of metabolism.

Authors:  C V Dang; G L Semenza
Journal:  Trends Biochem Sci       Date:  1999-02       Impact factor: 13.807

4.  Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules.

Authors:  Yan-Shen Shan; Jung-Hua Fang; Ming-Derg Lai; Meng-Chi Yen; Pin-Wen Lin; Hui-Ping Hsu; Chian-Yuh Lin; Yi-Ling Chen
Journal:  Mol Carcinog       Date:  2010-08-24       Impact factor: 4.784

5.  Mouse thyroid primary culture.

Authors:  L T Jeker; M Hejazi; C L Burek; N R Rose; P Caturegli
Journal:  Biochem Biophys Res Commun       Date:  1999-04-13       Impact factor: 3.575

6.  Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression.

Authors:  Sofia Asioli; Lori A Erickson; Alberto Righi; Long Jin; Marco Volante; Sarah Jenkins; Mauro Papotti; Gianni Bussolati; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2010-06-18       Impact factor: 7.842

Review 7.  Anaplastic thyroid carcinoma: palliation or treatment?

Authors:  Richard O Wein; Randal S Weber
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2011-04       Impact factor: 2.064

8.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

Authors:  Young H Ko; Barbara L Smith; Yuchuan Wang; Martin G Pomper; David A Rini; Michael S Torbenson; Joanne Hullihen; Peter L Pedersen
Journal:  Biochem Biophys Res Commun       Date:  2004-11-05       Impact factor: 3.575

10.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.

Authors:  Zhi Liu; Peng Hou; Meiju Ji; Haixia Guan; Kimberly Studeman; Kirk Jensen; Vasily Vasko; Adel K El-Naggar; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

View more
  8 in total

1.  microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.

Authors:  Aparna Lakshmanan; Anna Wojcicka; Marta Kotlarek; Xiaoli Zhang; Krystian Jazdzewski; Sissy M Jhiang
Journal:  Endocr Relat Cancer       Date:  2014-11-17       Impact factor: 5.678

2.  PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.

Authors:  Kristen Wong; Francesca Di Cristofano; Michela Ranieri; Daniela De Martino; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

3.  The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.

Authors:  Marika A Russo; Kristy S Kang; Antonio Di Cristofano
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

4.  PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.

Authors:  Daniela De Martino; Emrullah Yilmaz; Arturo Orlacchio; Michela Ranieri; Ke Zhao; Antonio Di Cristofano
Journal:  Cancer Lett       Date:  2018-09-19       Impact factor: 8.679

5.  Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.

Authors:  Valeria G Antico Arciuch; Marika A Russo; Mariavittoria Dima; Kristy S Kang; Florence Dasrath; Xiao-Hui Liao; Samuel Refetoff; Cristina Montagna; Antonio Di Cristofano
Journal:  Oncotarget       Date:  2011-12

6.  Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.

Authors:  Rebecca E Schweppe
Journal:  Front Endocrinol (Lausanne)       Date:  2012-06-19       Impact factor: 5.555

7.  The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.

Authors:  Carmela Passaro; Francesco Borriello; Viviana Vastolo; Sarah Di Somma; Eloise Scamardella; Vincenzo Gigantino; Renato Franco; Gianni Marone; Giuseppe Portella
Journal:  Oncotarget       Date:  2016-01-12

8.  SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance.

Authors:  Arturo Orlacchio; Michela Ranieri; Martina Brave; Valeria Antico Arciuch; Toni Forde; Daniela De Martino; Karen E Anderson; Phillip Hawkins; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2017-10-20       Impact factor: 12.701

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.